Gå direkt till huvudinnehållet

Rökavvänjning

Senast uppdaterad: Senast reviderad:
Sakkunnig:

  1. Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
  2. Socialstyrelsen. Nationella riktlinjer för prevention och behandling vid ohälsosamma levnadsvanor – Stöd för styrning och ledning. 2018 www.socialstyrelsen.se  
  3. Brunnhuber K, Cummings KM, Feit S, Sherman S, Woodcock J. Putting evidence into practice: Smoking cessation. BMJ Publishing Group: 2007.
  4. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2016; 3: CD008286. doi:10.1002/14651858.CD008286.pub3 DOI  
  5. Sæterdal I, Ringerike T, Odgaard-Jensen J, Harboe I, Hagen G, Reikvam A, Klemp M. Legemidler til røykeslutt. Rapport fra Kunnskapssenteret nr 08, 2010.
  6. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135-44. Canadian Medical Association Journal  
  7. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;5:CD000146. doi: 10.1002/14651858.CD000146.pub5. DOI  
  8. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 25 weeks. A randomized clinical trial. JAMA 2016; 315: 371-9. doi:10.1001/jama.2015.19284 DOI  
  9. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: a systematic review and meta-analysis. BMJ 2009; 338: b1024. BMJ (DOI)  
  10. Berlin I, Grangé G, Jacob N, Tanguy M-L. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014; 348: g1622. BMJ (DOI)  
  11. Oncken C, Dornelas E, Green J, et al. Nicotine gum for pregnant smokers: A randomized controlled trial. Obstet Gynekol 2008; 112: 859-67. PubMed  
  12. Ivan Berlin, Gilles Grangé, Nelly Jacob, Marie-Laure Tanguy. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014; 348. doi: 10.1136/bmj.g1622. (Published 11 March 2014)
  13. Piper ME, Fiore MC, Smith SS et al. Identifying effective intervention components for smoking cessation: a factorial screening experiment. Addiction. 2016 Jan;111(1):129-41. PMID: 26582269 PubMed  
  14. Anthenelli RM, Benowitz NL, West R et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387: 2507-20. pmid:27116918 PubMed  
  15. Thomas KH, Martin RM, Davies NM, et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practicee Research Datalink: prospective cohort study. BMJ 2013; 347: f5704. BMJ (DOI)  
  16. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2011; 2: CD006103. Cochrane (DOI)  
  17. Koegelenberg CFN, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation. JAMA 2014; 312: 155-161. Journal of the American Medical Association  
  18. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder. JAMA 2014; 311: 145-54. doi:10.1001/jama.2013.285113. PMID: 24399553 PubMed  
  19. Gunnel D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805. BMJ (DOI)  
  20. Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350: h1109. doi:http://dx.doi.org/10.1136/bmj.h1109
  21. FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease.
  22. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856. BMJ (DOI)  
  23. Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking. Arch Intern Med 2011; 171: 770-7. PubMed  
  24. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-200. New England Journal of Medicine  
  25. Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; 1: CD000031. pmid:24402784 PubMed  
  26. White AR, Rampes H, Ernst. Acupuncture for smoking cessation. Cochrane Database Syst Rev 2002; (2): CD000009. Cochrane (DOI)  
  27. Hartmann-Boyce J, Lancaster T, Stead LF. Print-based self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2014 Jun 3;6:CD001118. DOI: 10.1002/14651858.CD001118.pub3. DOI  
  • Hans Gilljam, seniorprofessor och läkare, Institutionen för folkhälsovetenskap, Karolinska institutet
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet